Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study

Autor: Kazunori Noguchi, Naoki Kamachi, Ryoko Kuromatsu, Taizo Yamaguchi, Tomotake Shirono, Masahito Nakano, Takumi Kawaguchi, Hironori Koga, Takashi Niizeki, Takuji Torimura, Shigeo Shimose, Yu Noda, Hideki Iwamoto, Shusuke Okamura, Masatoshi Tanaka, Hideya Suga
Rok vydání: 2021
Předmět:
Zdroj: Cancers, Vol 13, Iss 160, p 160 (2021)
Cancers
Volume 13
Issue 1
ISSN: 2072-6694
DOI: 10.3390/cancers13010160
Popis: We aimed to evaluate the impact of alternating lenvatinib (LEN) and trans-arterial therapy (AT) in patients with intermediate-stage hepatocellular carcinoma (HCC) after propensity score matching (PSM). This retrospective study enrolled 113 patients with intermediate-stage HCC treated LEN. Patients were classified into the AT (n = 41) or non-AT group (n = 72) according to the post LEN treatment. Overall survival (OS) was calculated using the Kaplan&ndash
Meier method and analyzed using a log-rank test after PSM. Factors associated with AT were evaluated using a decision tree analysis. After PSM, there were no significant differences in age, sex, etiology, or albumin-bilirubin (ALBI) score/grade between groups. The survival rate of the AT group was significantly higher than that of the non-AT group (median survival time
not reached vs. 16.3 months, P = 0.01). Independent factors associated with OS were AT and ALBI grade 1 in the Cox regression analysis. In the decision tree analysis, age and ALBI were the first and second splitting variables for AT. In this study, we show that AT may improve prognosis in patients with intermediate-stage HCC. Moreover, alternating LEN and trans-arterial therapy may be recommended for patients below 70 years of age with ALBI grade 1.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje